11/5/2026

speaker
Marisa
Conference Call Operator

Produced by Arvind Utchanah Music by Ben Thede Good morning, ladies and gentlemen. My name is Marissa and I will be your operator today. Welcome to Knight Therapeutics' third quarter 2026 results conference call. Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to IR at knighttx.com or via phone at 514-484-4483. I would like to remind everyone that this call is being recorded today, November 5th, 2026, and would now like to turn the meeting over to your host for today's call, Samira Sakhia, please go ahead, Ms. Sakhia.

speaker
Samira Sakhia
President and Chief Executive Officer, Knight Therapeutics

Thank you, Marisa. Good morning, everyone, and welcome to Knight Therapeutics' third quarter 2026 conference call. I'm joined on today's call by Amal Khouri, our Chief Business Officer, and Arvind Utchanah, our Chief Financial Officer. I'm pleased to report that this morning, not only did we announce record results for the first nine months of 2026, we also raised our revenue and adjusted EBITDA guidance for the year and increased our... The peak revenue potential of our pipeline and launch pipeline products. We reported $430 million of revenues and adjusted EBITDA of over $76 million representing a growth of 36% and 57% respectively compared to the same period last year. In fact, adjusted EBITDA for the first nine months of 2026 exceeded the adjusted EBITDA we reported for all of 2025. This strong performance is the result of our commercial execution, which drove a 39% growth in our promoted portfolio. On the business development front, we signed an exclusive distribution agreement with Kiowa Care and International for portalizer for certain LATAM countries, further strengthening our oncology and hematology portfolio. We also continue to advance our pipeline. Since the beginning of the third quarter, we submitted Gemtisa for regulatory approval in Canada, as well as Minjuvi for first-line diffused large B-cell lymphoma in Brazil. We obtained regulatory approval for TAVALYS in Colombia, Nictimbo in Brazil, and Minjuvi for follicular lymphoma in Mexico. We also launched Wenzora in Canada, TAVALYS in Brazil, Jurivast in Colombia and Peru, and Minjuvi for follicular lymphoma in Mexico. We have now executed 22 product launches since January of 2024. As we had previously disclosed, Knight had identified two generic submissions for liposomal amphotericin B under review by Anvisa. In September, a competitor received approval for a generic and a branded generic to Anvisa. We expect the launch of these products to negatively impact sales and adjusted EBITDA contributions of Ambizome in Brazil starting in 2027. On to the NCIB. We completed the program launched in August 2025 with a total purchase of nearly 2 million common shares at an average purchase price of $6.21 for aggregate cash consideration of $12 million. I will now turn the call over to Amal to provide more details on Potalyzo.

speaker
Amal Khouri
Chief Business Officer, Knight Therapeutics

Thank you, Samira. As Samira mentioned, this quarter we announced the signature of an exclusive distribution agreement with Keoa Kiran International for the commercialization of Potalyzo across certain Latin American countries. Potalyzo, or Mogamolizumab, is a first-in-class humanized monoclonal antibody that targets CCR4, which is a receptor expressed on malignant T-cells. Once Betaligio binds to CCR4 on these malignant cells, it increases the attraction of immune cells to destroy them. Betaligio is approved in the United States and Europe for adults with relapsed or refractory mycosis fungoids or cesarean syndrome after at least one prior systemic therapy. These two diseases are the most common subtypes of cutaneous T-cell lymphoma, which is a rare form of non-Hodgkin lymphoma. Patilajjo's approval is supported by the Maverick study, the largest randomized trial in this patient population, in which the product demonstrated significantly longer progression-free survival and a higher overall response rate compared to Vernastat. The unlicensing of Patilajjo illustrates Knight's position as a partner of choice and is the result of our continued focus on building our pipeline while leveraging our infrastructure. We look forward to making this much-needed treatment option Available to Patients in Latin America and we plan to submit to TELIGEO for approval over the coming months. I will now turn the call to Arvind to provide an update on our financial results.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation